PEDVU: Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Study Details
Study Description
Brief Summary
In this project the investigators study the safety and efficacy of the pipeline embolization device with vantage technology in treatment of unruptured brain aneurysms
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Evaluate 30-day morbidity rates [Done at 30 days post procedural]
We will evaluate short term clinical outcome in the form of morbidity rates 30 days after the procedure
- Evaluate 30-day mortality rates [Done at 30 days post procedural]
We will evaluate short term clinical outcome in the form of mortality rates 30 days after the procedure
Secondary Outcome Measures
- Evaluate 1-year morbidity rates [Done at >30days up to 1 year post procedural]
We will evaluate long term clinical outcome in the form of morbidity rates >30days up to 1 year after the procedure
- Evaluate 1-year mortality rates [Done at >30days up to 1 year post procedural]
We will evaluate long term clinical outcome in the form of mortality rates >30days up to 1 year after the procedure
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All patients treated with Pipeline Embolization Device with Vantage Technology (PEDV)
-
MRA and/or DSA (or tomographic angiography) available for follow up
Exclusion Criteria:
-
Insufficient background data available e.g., to determine size of aneurysm and pipeline device
-
PEDV used for causes other than aneurysms, e.g., fistulas and dissection.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Kings College Hospital | London | United Kingdom |
Sponsors and Collaborators
- King's College Hospital NHS Trust
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- 317314